NASDAQ:INKT MiNK Therapeutics (INKT) Stock Price, News & Analysis $12.20 -0.24 (-1.93%) Closing price 04:00 PM EasternExtended Trading$12.20 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About MiNK Therapeutics Stock (NASDAQ:INKT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MiNK Therapeutics alerts:Sign Up Key Stats Today's Range$12.10▼$12.8350-Day Range$10.38▼$12.7352-Week Range$8.48▼$16.93Volume28,582 shsAverage Volume20,880 shsMarket Capitalization$62.22 millionP/E RatioN/ADividend YieldN/APrice Target$35.00Consensus RatingHold Company Overview MiNK Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic invariant natural killer T (iNKT) cell therapies for the treatment of cancer. Its approach is designed to use the immune system’s natural ability to recognize and attack tumors while potentially enabling an off-the-shelf cell therapy model. The company’s lead product candidate is agenT-797, an allogeneic iNKT cell therapy being studied in patients with advanced solid tumors. MiNK has also evaluated agenT-797 in combination with other cancer treatments, including immune checkpoint inhibitors and cellular therapies, with the goal of improving responses in cancers that may be difficult to treat with existing approaches. MiNK Therapeutics was established to advance iNKT-based immunotherapies and conducts its development activities through clinical research and collaborations in oncology. The company is headquartered in New York and focuses primarily on developing treatments for patients with advanced or relapsed cancers.AI Generated. May Contain Errors. Read More MiNK Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks56th Percentile Overall ScoreINKT MarketRank™: MiNK Therapeutics scored higher than 56% of companies evaluated by MarketBeat, and ranked 395th out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingMiNK Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialMiNK Therapeutics has a consensus price target of $35.00, representing about 186.9% upside from its current price of $12.20.Amount of Analyst CoverageMiNK Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about MiNK Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for MiNK Therapeutics are expected to decrease in the coming year, from ($2.48) to ($2.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MiNK Therapeutics is -5.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MiNK Therapeutics is -5.08, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about MiNK Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.41% of the float of MiNK Therapeutics has been sold short.Short Interest Ratio / Days to CoverMiNK Therapeutics has a short interest ratio ("days to cover") of 3.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in MiNK Therapeutics has recently decreased by 12.05%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMiNK Therapeutics does not currently pay a dividend.Dividend GrowthMiNK Therapeutics does not have a long track record of dividend growth. News and Social Media2.8 / 5News Sentiment0.45 News SentimentMiNK Therapeutics has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for MiNK Therapeutics this week, compared to 2 articles on an average week.MarketBeat Follows2 people have added MiNK Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, MiNK Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders20.40% of the stock of MiNK Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions2.87% of the stock of MiNK Therapeutics is held by institutions.Read more about MiNK Therapeutics' insider trading history. Receive INKT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. INKT Stock News HeadlinesMiNK Therapeutics to Present Data on Treatment-Resistant Colorectal Cancer and Clearance of Senescent Tumor Cells and Fibroblasts at SITC 2026October 2 at 9:00 AM | globenewswire.comMink Therapeutics, Inc. Announces Selection of Clinical-Stage Agent-797 Inkt Platform for Arpa-H-Funded Initiative to Advance Room-Temperature Cell TherapyOctober 1, 2026 | marketscreener.comMThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.October 5 at 1:00 AM | Investors Alley (Ad)MiNK Therapeutics (NASDAQ:INKT) Shares Up 2.4% - Still a Buy?October 1, 2026 | americanbankingnews.comMiNK Selected For ARPA-H Program To Advance Room-Temperature Cell TherapySeptember 30, 2026 | rttnews.comMiNK Therapeutics’ agenT-797 Selected for ARPA-H BoSS Program to Advance Room-Temperature Cell Therapy StorageSeptember 30, 2026 | quiverquant.comQMiNK Therapeutics Selected for ARPA-H-Funded Initiative to Advance Room-Temperature Cell TherapySeptember 30, 2026 | globenewswire.comMiNK outlines 4-8 patients per site per month as U.S. ARDS enrollment starts in SeptemberAugust 14, 2026 | seekingalpha.comSee More Headlines INKT Stock Analysis - Frequently Asked Questions How have INKT shares performed this year? MiNK Therapeutics' stock was trading at $11.15 at the beginning of 2026. Since then, INKT stock has increased by 9.4% and is now trading at $12.20. How were MiNK Therapeutics' earnings last quarter? MiNK Therapeutics, Inc. (NASDAQ:INKT) announced its quarterly earnings data on Thursday, August, 13th. The company reported ($0.62) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by $0.02. Read the conference call transcript. When did MiNK Therapeutics' stock split? Shares of MiNK Therapeutics reverse split before market open on Tuesday, January 28th 2025.The 1-10 reverse split was announced on Tuesday, January 21st 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did MiNK Therapeutics IPO? MiNK Therapeutics (INKT) raised $43 million in an initial public offering on Thursday, October 14th 2021. The company issued 3,333,334 shares at a price of $12.00-$14.00 per share. How do I buy shares of MiNK Therapeutics? Shares of INKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of MiNK Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that MiNK Therapeutics investors own include Agenus (AGEN), HubSpot (HUBS), Meta Platforms (META), NVIDIA (NVDA), Tesla (TSLA) and Bank of America (BAC). Company Calendar Last Earnings8/13/2026Today10/05/2026Next Earnings (Estimated)11/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (14m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 INKT's financial health is in the Red zone, according to TradeSmith. INKT has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:INKT CIK1840229 Webwww.minktherapeutics.com Phone212-994-8250FaxN/AEmployees15Year Founded2017Price Target and Rating Average Price Target for MiNK Therapeutics$35.00 High Price Target$35.00 Low Price Target$35.00 Potential Upside/Downside+186.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($2.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.49 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-92.37% Debt Debt-to-Equity RatioN/A Current Ratio1.23 Quick Ratio1.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($3.03) per share Price / Book-4.03Miscellaneous Outstanding Shares5,100,000Free Float4,062,000Market Cap$62.22 million OptionableNo Data Beta0.47 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:INKT) was last updated on 10/5/2026 by MarketBeat.com Staff. From Our PartnersThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MiNK Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MiNK Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
